Similar articles

• Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.

  Stacy M, Galbreath A. Stacy M, et al. Clin Neuropharmacol. 2008 Jan-Feb;31(1):51-6. doi: 10.1097/WNF.0b013e318065b088. Clin Neuropharmacol. 2008. PMID: 18303491 Review.
• [Medical treatment of L-dopa induced dyskinesia].

  Kuno S. Kuno S. Nihon Rinsho. 2000 Oct;58(10):2110-4. Nihon Rinsho. 2000. PMID: 11068456 Review. Japanese. No abstract available.
• High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.

  Facca A, Sanchez-Ramos J. Facca A, et al. Mov Disord. 1996 May;11(3):327-9. doi: 10.1002/mds.870110319. Mov Disord. 1996. PMID: 8723153 No abstract available.
• Should levodopa be used anymore?

  Zegers de Beyl D. Zegers de Beyl D. Acta Neurol Belg. 2002 Dec;102(4):163-6. Acta Neurol Belg. 2002. PMID: 12534242 Review.
• [Sleep attacks and pergolide mesylate].

  García Ruiz PJ, Hernández J, Cantarero S, Fanjul S. García Ruiz PJ, et al. Neurologia. 2001 Feb;16(2):92. Neurologia. 2001. PMID: 11257938 Spanish. No abstract available.